Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669383 · ClinicalTrials.gov registry record · NA
Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants
A NA study of Respiratory Compliance and Functional Residual Capacity, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT00669383: Completed NA study of Respiratory Compliance and Functional Residual Capacity, sponsored by Oregon Health and Science University.
NCT00669383 is a NA study of Respiratory Compliance and Functional Residual Capacity that has completed, run by Oregon Health and Science University. The registered enrollment target is 85 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00669383, a NA study of Respiratory Compliance and Functional Residual Capacity, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. One course of antenatal steroids is the standard of care for threatened premature deliveries. It is unclear as to how long the benefit of one course of steroids last. The most benefit to the baby's lungs seem to occur if the steroids are given at least 24 hours before but within 7 days of a premature delivery. It is difficult to predict the timing of a preterm delivery so deliveries often do not occur within this time period. We hypothesize that the benefits of the steroids to the lungs wear off if the steroids are given more than 14 days before a preterm delivery, and that in these circumstances an extra course of steroids will help the premature baby's lungs and the premature baby will have less breathing problems as shown by lung function testing.
Conditions Studied
Interventions
- DRUG placebo
- DRUG betamethasone
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2001-06 |
| Est. Completion | 2009-11 |
| Phase | NA |
What the finished NCT00669383 record still lists
NCT00669383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Respiratory Compliance appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00669383 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00669383 about?
NCT00669383 is a clinical study titled "Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants". One course of steroids given to a mother before a premature delivery helps the lungs of the premature infant and decreases breathing problems. One course of antenatal steroids is the standard of care for threatened premature deliveries. It is unclear as to how long the benefit of one course of stero...
What is the current status of trial NCT00669383?
This trial is currently completed. It is a NA study. The enrollment target is 85 participants. The study started on 2001-06. Estimated completion is 2009-11.
What conditions does trial NCT00669383 study?
This clinical trial studies the following conditions: Respiratory Compliance, Functional Residual Capacity, Pulmonary Function Testing.
What interventions are being tested in trial NCT00669383?
The interventions under investigation include: placebo (DRUG), betamethasone (DRUG).
Who is sponsoring clinical trial NCT00669383?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00669383 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00669383's enrollment target sits among peer trials
85 980th of 2000 higher than 1,018 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia